[1] 赵泽华, 范建高. 2016年美国肝病年会非酒精性脂肪性肝病深度报道. 实用肝脏病杂志, 2017, 20:21-24.
[2] Goh GB, Mccullough AJ. Natural history of nonalcoholic fatty liver disease. Dig Dis Sci, 2016, 61:1226-1233.
[3] Njei B, Rotman Y, Ditah I, et al. Emerging trends in hepatocellular carcinoma incidence and mortality. Hepatology, 2015, 61:191-199.
[4] Ryerson AB, Eheman CR, Altekruse SF, et al. Annual report to the nation on the status of cancer, 1975-2012, featuring the increasing incidence of liver cancer. Cancer, 2016, 122:1312-1337.
[5] Younossi ZM, Otgonsuren M, Henry L, et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology, 2015, 62:1723-1730.
[6] 徐燕华, 欧强. 非酒精性脂肪性肝炎相关肝细胞癌研究进展. 肝脏, 2016, 21:1074-1076.
[7] Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology, 2010, 51:1820-1832.
[8] Park EJ, Lee JH, Yu GY, et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell, 2010, 140:197-208.
[9] Ikura Y, Mita E, Nakamori S. Hepatocellular carcinomas can develop in simple fatty livers in the setting of oxidative stress. Pathology, 2011, 43:167-168.
[10] Chang Q, Zhang Y, Beezhold KJ, et al.Sustained JNK1 activation is associated with altered histone H3 methylations in human liver cancer. J Hepatol, 2009, 50:323-333.
[11] Jung Y, Witek RP, Syn WK, et al.Signals from dying hepatocytes trigger growth of liver progenitors. Gut, 2010, 59:655-665.
[12] Wolf MJ, Adili A, Piotrowitz K, et al.Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes. Cancer Cell, 2014, 26:549-564.
[13] Ma C, Kesarwala AH, Eggert T, et al.NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis. Nature, 2016, 531:253-257.
[14] Liu YL, Patman GL, Leathart JB S, et al.Carriage of the PNPLA3, rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. J Hepatol, 2014, 61:75-81.
[15] Mittal S, Elserag HB, Sada YH, et al.Hepatocellular carcinoma in the absence of cirrhosis in US veterans is associated with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol, 2016, 14:124-131.
[16] Alexander J, Torbenson M, Wu TT, et al.Nonalcoholic fatty liver disease contributes to hepatocarcinogenesis in non-cirrhotic liver: a clinical and pathological study. J Gastroenterol Hepatol, 2013, 28:848-854.
[17] Mittal S, Sada YH, Elserag HB, et al.Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the Veteran Affairs Population. Clin Gastroenterol Hepatol, 2015, 13:594-601.
[18] Weinmann A, Alt Y, Koch S, et al.Treatment and survival of nonalcoholic steatohepatitis associated hepatocellular carcinoma. BMC Cancer, 2015, 15:1-9.
[19] Wong RJ, Cheung R, Ahmed A.Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the US. Hepatology, 2014, 59:2188-2195.
[20] Cauchy F, Zalinski S, Dokmak S, et al.Surgical treatment of hepatocellular carcinoma associated with the metabolic syndrome. Br J Surg, 2013, 100:113-121.
[21] Reddy SK, Steel JL, Chen HW, et al.Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steato-hepatitis versus hepatitis C and alcoholic liver disease. Hepatology, 2012, 55:1809-1819.
[22] Wong RJ, Chou C, Bonham CA, et al.Improved survival outcomes in patients with non-alcoholic steatohepatitis and alcoholic liver disease following liver transplantation: an analysis of 2002-2012 United Network for Organ Sharing data. Clin Transplant, 2014, 28:713-721.
[23] Hernandez-Alejandro R, Croome KP, Drage M, et al.A comparison of survival and pathologic features of non-alcoholic steatohepatitis and hepatitis C virus patients with hepatocellular carcinoma. World J Gastroenterol, 2012, 18:4145-4149.
[24] Wakai T, Shirai Y, Sakata J, et al.Surgical outcomes for hepatocellular carcinoma in nonalcoholic fatty liver disease. J Gastrointest Surg, 2011, 15:1450-1458.
[25] Takuma Y, Nouso K, Makino Y, et al.Outcomes after curative treatment for cryptogenic cirrhosis-associated hepatocellular carcinoma satisfying the Milan criteria. J Gastroenterol Hepatol, 2011, 26:1417-1424. |
